Dbv Technologies S A (DBVT) Stock News

DBV Technologies (DBVT) announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress from June 13-16, 2025, in Glasgow, UK. The company will present two significant posters and host a symposium focused on their VIASKIN patch platform. Key presentations include data showing reduced reactions from accidental peanut consumption in Year 2 of the EPITOPE trial extension, and results from the APTITUDE Phase 2 study evaluating a diagnostic patch for non-IgE mediated cow's milk allergy in infants. The symposium "Peanut Allergy: Recent Research Highlights" will be co-chaired by prominent allergy experts and will feature discussions on patient-allergist relationships and new clinical data on epicutaneous immunotherapy for peanut allergy.

DBV Technologies (DBVT) held its 2025 Combined General Meeting, where shareholders approved all resolutions proposed by the Board of Directors. The meeting was presided over by Michel de Rosen, Chairman of the Company. The voting results and resolutions have been made available on the company's website in the Investors/Annual General Meetings section.

DBV Technologies (DBVT) has reported its monthly voting rights and share count as of May 30, 2025. The company disclosed a total of 136,973,697 shares outstanding, with gross voting rights matching this figure at 136,973,697. The net total of voting rights, which excludes shares without voting rights, stands at 136,738,528. This disclosure is made in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers for companies listed on NYSE Euronext Paris.

DBV Technologies (DBVT) has filed an addendum to its 2024 Universal Registration Document with the French market authority (AMF). The addendum specifically updates the Board of Directors' Corporate Governance Report to include information about exceptional compensation granted to the Chief Executive Officer, as approved by the Board on April 30, 2025. This compensation payment requires shareholder approval at the upcoming Annual Combined General Meeting scheduled for June 11, 2025. Both the Universal Registration Document and addendum are accessible on DBV Technologies' website and the AMF website, with physical copies available at the company's headquarters in Châtillon, France.

DBV Technologies (DBVT) has announced its upcoming Combined General Meeting scheduled for June 11, 2025, at 2:00 PM CEST at the company's headquarters in Châtillon, France. The preliminary notice with agenda and draft resolutions was published in the French BALO on May 7, 2025, with the meeting notice to be published on May 21, 2025. Shareholders can access preparatory documents through the company's website and may request documents by contacting investors@dbv-technologies.com until June 6, 2025. The meeting will be available via live webcast, with a recording to be posted within seven business days after the event.

DBV Technologies (DBVT) has released its monthly voting rights disclosure for April 30, 2025. The company reported a total of 136,948,872 shares outstanding. The gross voting rights stand at 136,948,872, while the net voting rights amount to 136,762,549. This disclosure is made in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (AMF) for companies listed on NYSE Euronext Paris.

DBV Technologies (DBVT) has announced that its Chief Executive Officer, Daniel Tassé, will participate in a fireside chat at the Citizens JMP Life Sciences Conference. The event is scheduled for Wednesday, May 7, 2025, at 11:00am ET in New York, NY. Investors and interested parties can access a live webcast of the presentation through the company's website, and a replay will be available for 90 days following the event.

DBV Technologies reported its Q1 2025 financial results, showing a decrease in cash position to $13.0 million as of March 31, 2025, down from $32.5 million at the end of 2024. The company's net loss was $27.1 million, or $(0.26) per share, slightly improved from $27.3 million in Q1 2024.

Key financial highlights include:

• Operating expenses decreased to $27.4 million from $30.0 million year-over-year
• Research & Development costs remained stable at $21.5 million
• Operating income declined to $0.8 million from $1.4 million

Notably, the company secured a significant financing of up to $306.9 million on March 27, 2025, with initial proceeds of $125.5 million received in April 2025. This funding is intended to advance the Viaskin Peanut Patch through BLA submission and potential U.S. commercial launch. The company projects its current cash position will fund operations into June 2026.

DBV Technologies (DBVT) has announced the filing of its 2024 Annual Report on Form 10-K with the SEC and Universal Registration Document (URD) with the French AMF. The company's audited financial statements for the year ended December 31, 2024, were approved by the Board of Directors on April 11, 2025, showing no changes from the unaudited statements published on March 24, 2025.

The 2024 URD includes the Annual Financial Report, Management Report, Corporate Governance Report, and Share Buyback Program description. Both documents are accessible through the company's website, with the URD available on AMF's website and Form 10-K on SEC's website. Free printed copies can be obtained at DBV's headquarters in Châtillon, France.